A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults

Summary

The purpose of this study was to evaluate the efficacy of GSK3640254 + DTG relative to lamivudine (3TC) + DTG in treatment-naïve adult participants living with human immunodeficiency virus (HIV)-1. The participants were randomized to one of the three doses of blinded GSK3640254 (100, 150, or 200 milligrams \[mgs\]) or a reference arm of blinded 3TC-each in combination with open label DTG.

Timeline

Start

2021-08-18

Primary completion

2022-11-22

Completion

2023-05-11

Publications

• Joshi SR, Masia M, Mitha E, Castagna A, Cordova E, Ramgopal M, Gaudion A, Karthika S, Oyee J, Bainbridge V, Wynne B, Lataillade M. Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b study. EClinicalMedicine. 2025 Oct 17;89:103566. doi: 10.1016/j.eclinm.2025.103566. eCollection 2025 Nov.

Drugs

Indications